Alembic buys non-oncology division of Dabur Pharma

Alembic has acquired the domestic non-oncology formulation business of Dabur Pharma for a consideration of Rs. 159 crores. The acquisition will be funded through a combination of internal accruals and debt. The company may also exercise the option of diluting a small portion of its equity. The consideration of Rs. 159 crores is for the acquisition plus the actual net working capital.

Read the Indiainfoline.com article.

Dabur Pharma acquires Thailand-based Biosciences

Dabur India’s pharma subsidiary has acquired the sales and distribution network of a Thai-based associate. Dabur Pharma has acquired Biosciences its long-term partner in oncology products distribution and marketing, for an undisclosed amount. The deal will make the New Delhi-based Dabur Pharma the largest Asian company in the oncology segment.

The deal was funded from internal accruals. The company has been looking out for brand acquisitions for a long time and has also considered some products of the US-based Abbot Laboratories.

The $290 million Dabur Pharma is India’s largest player in the oncology segment and has marketing presence in more than 40 countries including the US and Europe. In addition to India and Thailand, it has major market share in South Asian countries such as Malaysia and Philippines. It develops, manufactures and markets a wide range of medicines from injectables and oral dosage forms to intermediates and active pharmaceutical ingredients across oncology and women’s health.

For more, read the articles in Business Standard and The Economic Times – 1 2.